speb/financial-data huggingface dataset:
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 93274800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 93274800000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 58902500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 58902500000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -236924700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -236924700000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 113485100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 113485100000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -2474400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -2474400000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Amortization: 2959200000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 2959200000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Assets Held For Sale Current: 1376900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Assets Held For Sale Current: 1376900000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 8817000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 8817000000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 294154702.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 294150273.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Basic EPS: 205.30
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 84.38
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 5535800000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 93612100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 93612100000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -91293300000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 10711900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 10711900000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 2946800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 2946800000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 4672100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 4672100000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 45557000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 45557000000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -20116500000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 4672100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 4672100000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -3169300000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: 7627200000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Change In Payable: -4755500000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -6075400000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -6710700000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -7552600000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Common Stock: 2946800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 2946800000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 707062100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 707062100000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 333100000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Common Stock Payments: -1002900000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 85917100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 85917100000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 175007800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 43489900000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Current Assets: 237372000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 237372000000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 2029800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 2029800000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Current Debt: 72502200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 72502200000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 74532000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 74532000000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 323649700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 323649700000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 3502100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 3502100000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Depreciation: 37190300000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 40149500000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 40149500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 11245700000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 37190300000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 11245700000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Derivative Product Liabilities: 0.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Derivative Product Liabilities: 0.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 294399800.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 294394497.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Diluted EPS: 205.13
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 84.31
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 60391100000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 24820400000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 941100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 941100000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 8100000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — EBIT: 91540800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — EBIT: 35758800000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — EBITDA: 131690300000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — EBITDA: 47004500000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: 37900000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — End Cash Position: 4672100000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Financial Assets: 8300700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets: 8300700000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 10654900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 10654900000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: 50757600000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 8591800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 8591800000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 15441000000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -3943900000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -563800000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 1378600000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Goodwill: 76817800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 76817800000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 86738000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 86738000000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 61376900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 61376900000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 1182205200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 1182205200000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Gross Profit: 574356700000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 187143300000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 109700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 109700000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Held To Maturity Securities: 501000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Held To Maturity Securities: 501000000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Interest Expense: 16259500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 4750400000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 16259500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 4750400000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Interest Income: 2923500000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 2923500000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -15397700000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 3420300000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Inventory: 95629800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 95629800000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 937372000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 937372000000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -165044500000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 19972900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 19972900000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 333100000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 94095700000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 211768900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 211768900000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 8682100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 8682100000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 157807700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 157807700000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 166489800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 166489800000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 73413200000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -5503100000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 3001200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 3001200000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 8920900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 8920900000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 689299900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 689299900000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 31865900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 31865900000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Minority Interests: -5300000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 72500000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: -111053900000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: -669800000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Net Debt: 225637800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 225637800000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 700500000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Net Income: 60391100000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Net Income: 24820400000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 60391100000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 24820400000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 60396400000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 24747900000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 60391100000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 24820400000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 60391100000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 24820400000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 75281300000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 60396400000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 24747900000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Net Interest Income: -13464300000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -4750400000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 32087200000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 88592600000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: 67910100000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -13464300000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -4750400000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Net Other Investing Changes: 100000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Net PPE: 945280500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 945280500000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -89506300000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 20682500000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 620324100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 620324100000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Non Current Accrued Expenses: 0.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Non Current Accrued Expenses: 0.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 0.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 0.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 650900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 650900000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 95794400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 95794400000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 10687200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 10687200000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 128242600000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 47098000000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Normalized Income: 57625010290.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 24895022639.35
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 106734300000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Operating Income: 84235100000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Operating Income: 34938700000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Operating Revenue: 749364500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 230633200000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 294146692.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 294146692.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Other Cash Adjustment Outside Changein Cash: 6651000000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 22472100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 22472100000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 61511200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 61511200000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 1744600000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 1744600000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 9920200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 9920200000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 1786400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 1786400000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: 13456200000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 29917700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 29917700000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 310600000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 310600000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 893500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 1021300000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 230805800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 79381900000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Other Payable: 6164700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 6164700000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Other Properties: 329000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 329000000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 11791900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 11791900000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 40884900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 40884900000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Other Special Charges: -963100000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Payables: 120276400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Payables: 120276400000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 21230700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 21230700000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Pretax Income: 75281300000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 31008400000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Properties: 101278200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Properties: 101278200000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 738000000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: -111416600000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -159066200000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -91293300000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 69501300000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 69501300000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 175007800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 43489900000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 40149500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 11245700000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 1774900000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 1774900000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -5503100000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Repurchase Of Capital Stock: -1002900000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 2193500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 2193500000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Restructuring And Mergern Acquisition: 880800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: 0.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 110394100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 110394100000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Sale Of Business: 362700000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 191153400000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 1787000000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 189756100000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 51761800000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 191134700000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Selling General And Administration: 51761800000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Share Issued: 294677410.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 294677410.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Short Term Debt Issuance: 20682500000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Special Income Charges: -11200000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: -93500000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Stock Based Compensation: 515600000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 707062100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 707062100000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 620324100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 620324100000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 681610290.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -18877360.65
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Tax Provision: 14884900000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 6260500000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.20
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.20
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 580000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 580000000.00
ULTRACEMCO.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -13006300000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Total Assets: 1336971600000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 1336971600000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 864869800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 864869800000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Total Debt: 241021800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 241021800000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 738928000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 738928000000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Total Expenses: 665129400000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 195694500000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 598043600000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 598043600000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 1099599600000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 1099599600000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 274393900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 274393900000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 128300000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 19895800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 19895800000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 3447700000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: -93500000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 3447700000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -93500000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Tradeand Other Payables Non Current: 2873600000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Tradeand Other Payables Non Current: 2873600000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Treasury Shares Number: 530718.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 530718.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Treasury Stock: 4169000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 4169000000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Work In Process: 15750300000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 15750300000.00
ULTRACEMCO.NS balance_sheet (annual, 2025-03-31) — Working Capital: -86277700000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: -86277700000.00
ULTRACEMCO.NS income_statement (annual, 2025-03-31) — Write Off: 93500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-03-31) — Write Off: 93500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 141528500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 212754500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 294158848.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 75.67
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 38190400000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 11067800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 11067800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 294392276.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 75.61
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 22259000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — EBIT: 34411000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — EBITDA: 45478800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 174564100000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 4333000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 4333000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Minority Interests: 49900000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Net Income: 22259000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 22259000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 22209100000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 22259000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 22259000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 22209100000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -4333000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -4333000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 45862600000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 22542391601.17
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Operating Income: 33035600000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 212754500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 1802300000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 74248600000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 30078000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 38190400000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 11067800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Restructuring And Mergern Acquisition: 0.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 46489700000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Selling General And Administration: 46489700000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: -383800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: -100408398.83
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 7868900000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.26
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 179718900000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: -383800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -383800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-06-30) — Write Off: 383800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 146936400000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 218296800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 294135697.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 58.66
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 44027000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 11819000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 11819000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 294336404.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 58.62
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 17254000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — EBIT: 27752200000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — EBITDA: 39571200000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 174269800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 4922000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 4922000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Minority Interests: -40400000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Net Income: 17254000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 17254000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 17294400000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 17254000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 17254000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 17294400000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -4922000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -4922000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 40463500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 17929937710.58
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Operating Income: 27333400000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 218296800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 1355800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 77126500000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Other Special Charges: 884800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 22830200000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 44027000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 11819000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Restructuring And Mergern Acquisition: 0.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 47577000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Selling General And Administration: 47577000000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -892300000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -216362289.42
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 5535800000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.24
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 190963400000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -892300000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -892300000.00
ULTRACEMCO.NS income_statement (quarterly, 2025-12-31) — Write Off: 7500000.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — +Operating Expense: 536501100000.00
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 163315800000.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — +Total Revenue: 873835200000.00
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 257994700000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 102367100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 102367100000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 60287500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 60287500000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -281112500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -281112500000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Additional Paid In Capital: 113493800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 113493800000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -2522400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -2522400000.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — Amortization: 4152400000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Amortization Cash Flow: 2019600000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Assets Held For Sale Current: 1456900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 1456900000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 8642000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 8642000000.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 294130875.00
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 294128784.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — Basic EPS: 277.62
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 101.41
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 4672100000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 102081100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 102081100000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -96777700000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 9744300000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 9744300000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 2946800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 2946800000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 3544800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 3544800000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 52338000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 52338000000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -22733600000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Cash Financial: 3544800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Cash Financial: 3544800000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -679200000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -8403000000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Change In Payable: 5902800000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -276000000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -2331700000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -1177900000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Common Stock: 2946800000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 2946800000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 766235400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 766235400000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 500100000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Common Stock Payments: -1193500000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 96037400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 96037400000.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 214885200000.00
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 50756800000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Current Assets: 252474400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 252474400000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 2227100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 2227100000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Current Debt: 77618400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 77618400000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 79845500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 79845500000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 338317000000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 338317000000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 3548400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 3548400000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Depreciation: 44425000000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 46444600000.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 46444600000.00
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 12081000000.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 42292200000.00
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 12081000000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Derivative Product Liabilities: 0.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Derivative Product Liabilities: 0.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 294313417.00
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 294302911.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — Diluted EPS: 277.45
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 101.35
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 81656400000.00
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 29827600000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Dividends Payable: 1073100000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 1073100000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 0.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — EBIT: 127382400000.00
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — EBIT: 44674600000.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — EBITDA: 173827000000.00
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — EBITDA: 56755600000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: 50600000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — End Cash Position: 3544800000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Financial Assets: 14625600000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Financial Assets: 14625600000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 17811400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 17811400000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -59535700000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 7628400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 7628400000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 56380900000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -1914200000.00
ULTRACEMCO.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: -408500000.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 1672900000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Goodwill: 79090500000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 79090500000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 93653300000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 93653300000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 62809900000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 62809900000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 1276096200000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 1276096200000.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — Gross Profit: 658950000000.00
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 207237900000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Hedging Assets Current: 71400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Hedging Assets Current: 71400000.00
ULTRACEMCO.NS balance_sheet (annual, 2026-03-31) — Held To Maturity Securities: 391400000.00
ULTRACEMCO.NS balance_sheet (quarterly, 2026-03-31) — Held To Maturity Securities: 391400000.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — Interest Expense: 18110500000.00
ULTRACEMCO.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 4869200000.00
ULTRACEMCO.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 18110500000.00